At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the company highlighted applications of the technology in the context of neurodegenerative disease, cancer, and metabolic disease. Seer also announced a co-marketing and sales agreement with Thermo Fisher Scientific to jointly promote Proteograph alongside Thermo Scientific Orbitrap Astral
mass spectrometers to provide customers of the Orbitral Astral an integrated solution for unbiased proteomic analysis.
The list of presentations at ASHG, which was held in Denver, CO, included one from healthcare company PrognomiQ focused on lung cancer. Philip Ma, PhD, CEO and founder of PrognomiQ, a spin-out from Seer, and his team are exploring a multi-omics biomarker test that uses proteomics, transcriptomics, and metabolomics to detect early-stage lung cancer.
Earlier this year, the company shared…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
